Hematologic Oncology | Specialty

PI3K Inhibitors for R/R Follicular Lymphoma

March 15th 2021

Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.

R/R DLBCL: Transplants in the Era of CAR-T

March 12th 2021

CAR T for R/R DLBCL: Improving Access and Utilization

March 12th 2021

FDA Extends Review Period for Belumosudil in Chronic GVHD

March 11th 2021

The FDA has extended the review period for the new drug application for belumosudil for use in patients with chronic graft-versus-host disease to allow for more time to review additional data submitted by the biopharmaceutical company.

ASH Takeaways and Future Directions for Multiple Myeloma

March 11th 2021

Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management. 

Sequencing BCMA-Targeted Agents in RRMM

March 11th 2021

Insights on approaching the sequencing of BCMA-targeted agents and whether antigen loss is considered an issue in RRMM. 

Non-BCMA Specific Targets in RRMM

March 11th 2021

Examining non-BCMA BiTE (bispecific T-cell engager) approaches to therapy, such as talquetamab and BFCR4350A, for the treatment of RRMM. 

Dr. Goy on the Efficacy of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

March 10th 2021

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

Dr. Neelapu on Managing Toxicities Associated with CAR T-Cell Products in Lymphoma

March 10th 2021

Sattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.

Venetoclax/HMA Approach Revolutionizes Care for Certain Subsets of AML

March 10th 2021

Kira Gritsman, MD, PhD, discusses the significance of the VIALE-A trial examining venetoclax plus azacitidine in older patients with AML and the emergence of minimal residual disease as an important end point in clinical trials.

Polycythemia Vera: An Update on Clinical Trials

March 10th 2021

Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.

PV Progression and Guideline-Directed Management

March 10th 2021

Ruben A. Mesa, MD, highlights signs of disease progression and the utilization of guideline recommendations in the occurrence of a thrombotic event when treating polycythemia vera.

D’Angelo Details Combos Designed to Produce Durable Activity in Relapsed/Refractory DLBCL

March 9th 2021

Christopher D'Angelo, MD, discusses emerging CAR T-cell therapies and the challenges with using a 5-drug regimen.

Belumosudil: Poised to Become Necessity in Chronic GVHD

March 9th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the potential clinical implications should belumosudil gain FDA approval in chronic GVHD.

Frontline Ibrutinib Shows Sustained Survival Benefit in TP53-Aberrant CLL

March 8th 2021

Ibrutinib as a frontline treatment led to sustained efficacy and impressive 4-year progression-free and overall survival rates in patients with chronic lymphocytic leukemia who have TP53 aberrations.

Use of APR-246 and Oral HMAs in AML

March 8th 2021

Role of Transplant in AML

March 8th 2021

R/R Follicular Lymphoma: Third-Line Treatment Options

March 8th 2021

Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.

Transplantation for R/R Follicular Lymphoma

March 8th 2021

The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.

FDA Approves Axi-Cel for Relapsed/Refractory Indolent Follicular Lymphoma

March 6th 2021

The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory indolent follicular lymphoma after 2 or more lines of systemic therapy.